198 related articles for article (PubMed ID: 31137989)
1. Efficacy of hyperthermic intraperitoneal chemotherapy in patients with epithelial ovarian cancer: a meta-analysis.
Wu Q; Wu Q; Xu J; Cheng X; Wang X; Lu W; Li X
Int J Hyperthermia; 2019; 36(1):562-572. PubMed ID: 31137989
[No Abstract] [Full Text] [Related]
2. Prognostic value and adverse events of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in primary advanced and platinum-sensitive recurrent epithelial ovarian cancer: a systematic review and meta-analysis.
Xia Y; Wang H; Zhang J; Wang Y
Int J Hyperthermia; 2023; 40(1):2165729. PubMed ID: 36775583
[TBL] [Abstract][Full Text] [Related]
3. Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis.
Kim SI; Kim JH; Lee S; Cho H; van Driel WJ; Sonke GS; Bristow RE; Park SY; Fotopoulou C; Lim MC
Gynecol Oncol; 2022 Dec; 167(3):547-556. PubMed ID: 36273925
[TBL] [Abstract][Full Text] [Related]
4. Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis.
Bouchard-Fortier G; Cusimano MC; Fazelzad R; Sajewycz K; Lu L; Espin-Garcia O; May T; Bouchard-Fortier A; Ferguson SE
Gynecol Oncol; 2020 Jul; 158(1):218-228. PubMed ID: 32387131
[TBL] [Abstract][Full Text] [Related]
5. Ten-year treatment outcomes of consolidation hyperthermic intraperitoneal chemotherapy for ovarian cancer (HIPEC-KOV-03R).
Yoo JG; Kim JH; Park EY; Kim I; Lim MC; Lee SJ
J Gynecol Oncol; 2023 Nov; 34(6):e72. PubMed ID: 37417300
[TBL] [Abstract][Full Text] [Related]
6. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysis.
Huo YR; Richards A; Liauw W; Morris DL
Eur J Surg Oncol; 2015 Dec; 41(12):1578-89. PubMed ID: 26453145
[TBL] [Abstract][Full Text] [Related]
7. Hyperthermic Intraperitoneal Chemotherapy in the Management of Primary Epithelial Ovarian Cancer: A Debated Issue for Gynecologic Oncologists.
Gadducci A; Cosio S; Lippolis PV
Anticancer Res; 2022 Oct; 42(10):4659-4665. PubMed ID: 36191972
[TBL] [Abstract][Full Text] [Related]
8. Dense hyperthermic intraperitoneal chemotherapy with cisplatin in patients with stage III serous epithelial ovarian cancer: a retrospective study.
He X; Wei L; Li R; Jing S; Jia L; Ji D; Li Y; Wang Y; Zhu Y
BMC Cancer; 2021 Jun; 21(1):738. PubMed ID: 34176478
[TBL] [Abstract][Full Text] [Related]
9. Effects of CytoReductive surgery plus hyperthermic IntraPEritoneal chemotherapy (HIPEC) versus CytoReductive surgery for ovarian cancer patients: A systematic review and meta-analysis.
Wang Y; Ren F; Chen P; Liu S; Song Z; Ma X
Eur J Surg Oncol; 2019 Mar; 45(3):301-309. PubMed ID: 30786961
[TBL] [Abstract][Full Text] [Related]
10. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
[TBL] [Abstract][Full Text] [Related]
11. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials.
Filis P; Mauri D; Markozannes G; Tolia M; Filis N; Tsilidis K
ESMO Open; 2022 Oct; 7(5):100586. PubMed ID: 36116421
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival in patients with epithelial ovarian cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Le Saux O; Decullier E; Freyer G; Glehen O; Bakrin N
Int J Hyperthermia; 2018; 35(1):652-657. PubMed ID: 30295114
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy.
Lim SL; Havrilesky LJ; Habib AS; Secord AA
Gynecol Oncol; 2019 May; 153(2):376-380. PubMed ID: 30718126
[TBL] [Abstract][Full Text] [Related]
14. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study.
Deraco M; Virzì S; Iusco DR; Puccio F; Macrì A; Famulari C; Solazzo M; Bonomi S; Grassi A; Baratti D; Kusamura S
BJOG; 2012 Jun; 119(7):800-9. PubMed ID: 22571746
[TBL] [Abstract][Full Text] [Related]
15. Selection of patients with ovarian cancer who may show survival benefit from hyperthermic intraperitoneal chemotherapy: A systematic review and meta-analysis.
Kim SI; Cho J; Lee EJ; Park S; Park SJ; Seol A; Lee N; Yim GW; Lee M; Lim W; Song G; Chang SJ; Kim JW; Kim HS
Medicine (Baltimore); 2019 Dec; 98(50):e18355. PubMed ID: 31852138
[TBL] [Abstract][Full Text] [Related]
16. Secondary cytoreductive surgery, hyperthermic intraperitoneal intraoperative chemotherapy, and chemotherapy alone: a retrospective comparison of alternative approaches in relapsed platinum sensitive ovarian cancer.
Marocco F; Vaira M; Milani A; Genta S; Maggiorotto F; Magistris A; Cinquegrana A; Robella M; De Simone M; Aglietta M; Ponzone R; Valabrega G
Eur J Gynaecol Oncol; 2016; 37(5):638-643. PubMed ID: 29787001
[TBL] [Abstract][Full Text] [Related]
17. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer.
Harter P; Bogner G; Chiva L; Cibula D; Concin N; Fotopoulou C; Gonzalez-Martin A; Guyon F; Heinzelmann-Schwarz V; Kridelka F; Mahner S; Marmé F; Marth C; Morice P; Novák Z; Papadia A; Ray-Coquard I; Redecha M; Redondo A; Schwameis R; Sehouli J; Undurraga M; Van Gorp T; Vergote I
Bull Cancer; 2024 Mar; 111(3):277-284. PubMed ID: 36967330
[TBL] [Abstract][Full Text] [Related]
18. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Robella M; Vaira M; Marsanic P; Mellano A; Borsano A; Cinquegrana A; Sottile A; De Simone M
Minerva Chir; 2014 Feb; 69(1):27-35. PubMed ID: 24675244
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: A pilot study of 31 patients.
Frenel JS; Leux C; Pouplin L; Ferron G; Berton Rigaud D; Bourbouloux E; Dravet F; Jaffre I; Classe JM
J Surg Oncol; 2011 Jan; 103(1):10-6. PubMed ID: 21031424
[TBL] [Abstract][Full Text] [Related]
20. A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer.
Chiva LM; Gonzalez-Martin A
Gynecol Oncol; 2015 Jan; 136(1):130-5. PubMed ID: 25434634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
